• 1
    Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 51827.
  • 2
    Singer CF, Gschwantler-Kaulich D, Fink-Retter A et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008; 110: 27381.
  • 3
    Sheehan KM, Gulmann C, Eichler GS et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial–mesenchymal transition. Oncogene 2008; 27: 32331.
  • 4
    Hasegawa M, Furuya M, Kasuya Y et al. CD151 dyanmicx in carcinoma–stroma interaction: integrin expression, adhesion strength and proteolytic activity. Lab Invest 2007; 87: 88292.
  • 5
    Loussouarn D, Campion L, Sagan C et al. Prognostic impact of syndecan-1 expression in invasive ductal carcinomas. Br J Cancer 2008; 98: 19938.
  • 6
    Studebaker AW, Storci G, Werbeck JL et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008; 68: 908795.
  • 7
    Hasebe T, Tsuda H, Hirohashi S et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998; 49: 195208.
  • 8
    Hasebe T, Sasaki S, Imoto S et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol 2002; 15: 50216.
  • 9
    Colpaert C, Vermeulen PB, Van Beest P et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001; 39: 41625.
  • 10
    Baak JP, Colpaert CG, Van Diest PJ et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 2005; 41: 2093101.
  • 11
    Hasebe T, Imoto S, Ogura T et al. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast. Jpn J Cancer Res 1997; 88: 87785.
  • 12
    Hasebe T, Sasaki S, Imoto S et al. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000; 156: 170110.
  • 13
    Hasebe T, Sasaki S, Imoto S et al. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol 2001; 14: 32537.
  • 14
    Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81137.
  • 15
    Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991; 253: 4953.
  • 16
    Kastan MB, Bartek J. Cell-cycle check-points and cancer. Nature 2004; 432: 31623.
  • 17
    Kurose K, Gilley S, Matsumoto PH et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinoma. Nat Genet 2002; 32: 3557.
  • 18
    Hill R, Song Y, Cardiff RD et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2006; 123: 100111.
  • 19
    Bierie B, Moses HL. Under pressure: stromal fibroblasts change their ways. Cell 2005; 123: 9857.
  • 20
    Moinfar F, Man YG, Arnould L et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implication for tumorigenesis. Cancer Res 2000; 60: 25626.
  • 21
    Patocs A, Zhang Li, Xu Y et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. New Engl J Med 2007; 357: 254351.
  • 22
    Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors, 6th edn. Geneva: Wiley-Liss, 2002.
  • 23
    Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 35977.
  • 24
    Gilchrist KW, Gray R, Fowble B et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol 1993; 11: 192935.
  • 25
    Hasebe T, Imoto S, Sasaki S et al. A proposal for a new histological classification scheme for predicting short-term tumor recurrence and death in patients with invasive ductal carcinoma of the breast. Jpn J Cancer Res 1998; 89: 135873.
  • 26
    Allred DC, Harvey JM, Berardo MD et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 15568.
  • 27
    Harvey JM, Clark GM, Osborne K et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 147481.
  • 28
    Mohsin S, Weiss H, Havighurst T et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004; 17: 154554.
  • 29
    Badve SS, Baehner FL, Gray RP et al. Estrogen- and progesterone-receptor status in ECOG2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008; 26: 247381.
  • 30
    Allred DC, Clark GM, Elledge R et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 2006.
  • 31
    Wolff AC, Hammond ME, Schwartz JN et al. American Scociety of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 1843.
  • 32
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 33
    Kiaris H, Chatzistamou I, Trimis G et al. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 2005; 65: 162730.
  • 34
    Allinen M, Beroukhim R, Cai L et al. Molecular characterization of the tumor microenviroment in breast cancer. Cancer Cell 2004; 6: 1732.
  • 35
    Lebret SC, Newgreen DF, Thompson EW et al. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 2007; 9: R19.
  • 36
    Campbell IG, Qiu W, Polyak K et al. Breast-cancer stromal cells with TP53 mutations. New Engl J Med 2008; 10: 16345.
  • 37
    Hasebe T, Imoto S, Yokose T et al. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 2008; 39: 68193.